Special ReportsAll NewsFDA BriefsOncology IconsThe Targeted PulseVoices from the Field
Conference CoverageConference ListingData Dialogue with the Oncology Brothers
All VideosCase-Based Peer PerspectivesEvolving Paradigms in OncologyExpert Perspective Virtual Tumor BoardInterviewsInvestigator PerspectivesMedical World NewsPersonalized MedicinePivotal Practice Views with the Oncology BrothersPodcastsSpeaking Out
All PublicationsEvolving ParadigmsPeers & Perspectives in OncologyTargeted Therapies in Oncology
CASE-BASED ROUNDTABLEPARTNERS
CME/CEClinical TrialsEventsPrecision Medicine PerspectivesPress ReleasesSponsored ContentTreatment Resources
SUBSCRIBE
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
Spotlight -
  • Biomarker-Driven Lung Cancer
  • GIST
  • HER2 Breast Cancer
  • Chronic Lymphocytic Leukemia
  • Small Cell Lung Cancer
  • Renal Cell Carcinoma
BRAIN CANCER
BREAST CANCERBREAST CANCER
GENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERSGENITOURINARY CANCERS
GENOMIC TESTINGGENOMIC TESTING
GI CANCERSGI CANCERSGI CANCERSGI CANCERSGI CANCERS
GYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERSGYNECOLOGIC CANCERS
HEAD & NECK CANCERS
HEMATOLOGYHEMATOLOGY
IMMUNOTHERAPYIMMUNOTHERAPY
LEUKEMIASLEUKEMIASLEUKEMIASLEUKEMIAS
LUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCERLUNG CANCER
LYMPHOMASLYMPHOMASLYMPHOMASLYMPHOMAS
MPNs
MULTIPLE MYELOMA
NTRK GENE FUSIONS
SARCOMA
SKIN CANCERSSKIN CANCERS
THYROID CANCERS
    • CASE-BASED ROUNDTABLE
    • PARTNERS
    • SUBSCRIBE
Advertisement

Trending News on Targeted Oncology, Week of April 3, 2020

April 3, 2020
By Danielle Ternyila
Article

Targeted Oncology reviews trending news and videos online for the week of April 3, 2020, including recent updates on the impact of COVID-19 in oncology practice and other FDA news.

The FDA continues to work towards improving the treatment landscape for patients with cancer and also granted approval to a combination regimen for the treatment of patients with extensive-stage small cell lung cancer.

Among other news this week atTargeted Oncology, Kashyap Patel, MD, BCMAS; Natasha Clinton, MSN, APRN, AOCNP, BCMAS; Hirangi Mukhi, BS; Maharshi Patel, BS, MBA, spoke to the opportunity of a potentially expanded role for precision medicine, while Pashtoon M. Kasi, MD, MBBS, MS reviewed rare subsets of colon cancer.

These updates and others were trending this week:

Leronlimab Continues to Improve Health in Patients with Novel Coronavirus

The FDA provided clearance for the initiation and immediate enrollment of a new phase II trial exploring the investigational oncologic agent leronlimab as treatment of patients with coronavirus disease 2019 (COVID-19) who experience mild to moderate respiratory complications.

FDA Approves Durvalumab for Extensive-Stage Small Cell Lung Cancer

On March 30, 2020, the FDA approved durvalumab (Imfinzi) in combination with standard-of-care chemotherapy, etoposide and carboplatin or cisplatin, as a frontline treatment for adult patients with extensive-stage small cell lung cancer.

COVID-19 Presents an Opportunity for Precision Medicine to Play Expanded Role in Care

A sudden surge in the cases of COVID-19 due to pandemic, along with efforts to contain it, has led to multiple challenges that no country has experienced in the last several decades. The global pandemic from COVID-19 poses a unique set of challenges not only for patients with cancer who need their treatment, but also for caregivers, oncologists, and the overall care team.

Tweet Chat Recap: Evaluating Treatment Options for Rare Subsets of Colorectal Cancer

To conclude the month of March, Colorectal Cancer (CRC) Awareness Month,Targeted Oncologywas joined by Pashtoon M. Kasi, MD, MBBS, MS, in a tweet chat to discuss 3 individual cases of CRC, which highlighted a variety of subsets of CRC like the NTRKfusions, BRAFmutations, and HER2 amplifications. 

A Look Back at FDA News from March 2020

Take a look back at all the FDA happenings from the month of March 2020, including 4 new approvals and several Fast Track, Priority Review, Breakthrough Therapy, and Orphan Drug designations.

Videos:

Immunotherapy Induces Responses in Subtypes of Sarcomas

Jonathan C. Trent, MD, PhD, a professor and associate director for Clinical Research at the Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses some of the recent immunotherapeutic advances in the treatment landscape for patients with sarcoma, particularly with immune checkpoint inhibitors.

Expert Perspective Tumor Board: Skin Cancer

Case 3: Recurrent Metastatic cSCC

Newsletter

Stay up to date on practice-changing data in community practice.

Subscribe Now!
Recent Videos
1 expert in this video
3 experts are featured in this series.
1 expert in this video
3 experts are featured in this series.
Related Content

Biomarker Testing Expands in Metastatic Bladder Cancer

Biomarker Testing Expands in Metastatic Bladder Cancer

Jordyn Sava
May 21st 2025
Article

Lisa Herms, PhD, discussed findings from a retrospective analysis from the US community oncology setting on biomarker testing for bladder cancer.

Read More


Predicting Palbociclib Outcomes in Breast Cancer Using Deep Learning

Predicting Palbociclib Outcomes in Breast Cancer Using Deep Learning

Jordyn Sava;Xiaojie Zhang, MD;Akshat Singhal, PhD
April 15th 2025
Podcast

Xiaojie Zhang, MD, and Akshat Singhal, PhD, discuss their research leveraging deep learning to predict how patients with ER+/HER2- breast cancer will respond to palbociclib.

Listen


Hope on the Horizon: Brain Cancer Advances in Awareness Month

Hope on the Horizon: Brain Cancer Advances in Awareness Month

Jordyn Sava
May 21st 2025
Article

Manmeet Ahluwalia, MD, MBA, FASCO, discussed the importance of Brain Cancer Awareness Month for a community oncologist audience.

Read More


BMT CTN 1902 in Myeloma: Key Findings With Garfall

BMT CTN 1902 in Myeloma: Key Findings With Garfall

Jordyn Sava;Alfred L. Garfall, MD, MS
March 13th 2025
Podcast

In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.

Listen


CAR T Toxicity Differences Seen in Transplant-Ineligible LBCL

CAR T Toxicity Differences Seen in Transplant-Ineligible LBCL

Targeted Oncology Staff
May 20th 2025
Article

During a live event, Nathan M. Denlinger, DO, MS, discussed the PILOT and ALYCANTE trials of CAR T-cell therapy in transplant-ineligible B-cell lymphoma.

Read More


ODAC Votes Daratumumab Benefits Smoldering MM

ODAC Votes Daratumumab Benefits Smoldering MM

Sabrina Serani
May 20th 2025
Article

In a 6 to 2 vote, the Oncologic Drug Advisory Committee determined that findings from the phase 3 AQUILA trial do/do not support a positive benefit-risk ratio for patients with smoldering multiple myeloma.

Read More

Related Content

Biomarker Testing Expands in Metastatic Bladder Cancer

Biomarker Testing Expands in Metastatic Bladder Cancer

Jordyn Sava
May 21st 2025
Article

Lisa Herms, PhD, discussed findings from a retrospective analysis from the US community oncology setting on biomarker testing for bladder cancer.

Read More


Predicting Palbociclib Outcomes in Breast Cancer Using Deep Learning

Predicting Palbociclib Outcomes in Breast Cancer Using Deep Learning

Jordyn Sava;Xiaojie Zhang, MD;Akshat Singhal, PhD
April 15th 2025
Podcast

Xiaojie Zhang, MD, and Akshat Singhal, PhD, discuss their research leveraging deep learning to predict how patients with ER+/HER2- breast cancer will respond to palbociclib.

Listen


Hope on the Horizon: Brain Cancer Advances in Awareness Month

Hope on the Horizon: Brain Cancer Advances in Awareness Month

Jordyn Sava
May 21st 2025
Article

Manmeet Ahluwalia, MD, MBA, FASCO, discussed the importance of Brain Cancer Awareness Month for a community oncologist audience.

Read More


BMT CTN 1902 in Myeloma: Key Findings With Garfall

BMT CTN 1902 in Myeloma: Key Findings With Garfall

Jordyn Sava;Alfred L. Garfall, MD, MS
March 13th 2025
Podcast

In this episode of Targeted Talks, Alfred L. Garfall, discusses the phase 2 BMT CTN 1902 trial of idecabtagene vicleucel in patients with multiple myeloma.

Listen


CAR T Toxicity Differences Seen in Transplant-Ineligible LBCL

CAR T Toxicity Differences Seen in Transplant-Ineligible LBCL

Targeted Oncology Staff
May 20th 2025
Article

During a live event, Nathan M. Denlinger, DO, MS, discussed the PILOT and ALYCANTE trials of CAR T-cell therapy in transplant-ineligible B-cell lymphoma.

Read More


ODAC Votes Daratumumab Benefits Smoldering MM

ODAC Votes Daratumumab Benefits Smoldering MM

Sabrina Serani
May 20th 2025
Article

In a 6 to 2 vote, the Oncologic Drug Advisory Committee determined that findings from the phase 3 AQUILA trial do/do not support a positive benefit-risk ratio for patients with smoldering multiple myeloma.

Read More

About Us
Advertise
Contact Us
CureToday.com
CancerNetwork.com
OncLive.com
OncNursingNews.com
Do Not Sell My Information
Privacy
Terms & Conditions
Editorial Board
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.